INDIANAPOLIS, October 19, 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) — Roche Diagnostics Corporation was recently designated a 2021 Military Friendly® Employer by VIQTORY Media, ranking as No. 8 overall for companies with $1-5 billion in revenue. Military Friendly® rankings distinguish high pedigree organizations with robust, comprehensive veteran and military spouse employment, transition, retention and career development programs that ultimately improve the lives of veterans.
Roche will be showcased along with other 2021 Military Friendly® Employers in the December issue of G.I. Jobs® magazine, which is distributed to Transition Assistance Program centers globally to reach our veteran community. The list can also be found on militaryfriendly.com.
Organizations earning the Military Friendly® Employer designation were evaluated using both public and government data sources with responses from a comprehensive survey completed by the employer.
The methodology, criteria, and weightings were determined by VIQTORY with input from the Military Friendly Advisory Council of independent leaders in the higher education and military recruitment community. Final ratings were determined by combining an organization’s survey score with an assessment of the organization’s ability to meet thresholds for Applicant, New Hire Retention, Employee Turnover, and Promotion & Advancement of veterans and military employees.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognized as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.